Literature DB >> 16998949

Complete blindness after optic neuropathy induced by short-term linezolid treatment in a patient suffering from muscle dystrophy.

Leonard Azamfirei1, Sanda-Maria Copotoiu, Klara Branzaniuc, Janos Szederjesi, Ruxandra Copotoiu, Cristina Berteanu.   

Abstract

We present a case of severe optic neuropathy following linezolid treatment, which led to complete irreversible blindness, in a patient with progressive muscular dystrophy, treated with linezolid for 16 days for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Interruption of antibiotic therapy did not lead to remission of ocular symptoms. Administration of linezolid may lead to severe neuropathy even in the case of short-term treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 16998949     DOI： 10.1002/pds.1320

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


  8 in total

1.  Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.

Authors:  Shawn Flanagan; Edward E McKee; Debaditya Das; Paul M Tulkens; Hiromi Hosako; Jill Fiedler-Kelly; Julie Passarell; Ann Radovsky; Philippe Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

2.  Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism, and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically Relevant Concentrations in Cultured Human HL-60 Promyelocytes and THP-1 Monocytes.

Authors:  Tamara V Milosevic; Valéry L Payen; Pierre Sonveaux; Giulio G Muccioli; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

3.  Early onset probable linezolid-induced encephalopathy.

Authors:  Jeffery Fletcher; Laura E Aykroyd; Eric C Feucht; James M Curtis
Journal:  J Neurol       Date:  2009-11-05       Impact factor: 4.849

4.  Linezolid-associated optic neuropathy in a patient with ocular sarcoidosis.

Authors:  Katsuji Kiuchi; Miki Miyashiro; Chiemi Kitagawa; Sanae Wada
Journal:  Jpn J Ophthalmol       Date:  2009-09-08       Impact factor: 2.447

Review 5.  Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.

Authors:  Aliasgar Esmail; Natasha F Sabur; Ikechi Okpechi; Keertan Dheda
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 6.  Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.

Authors:  Mathias W Pletz; O Burkhardt; T Welte
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

Review 7.  A Review of Mitochondrial Optic Neuropathies: From Inherited to Acquired Forms.

Authors:  Yasmine L Pilz; Sherry J Bass; Jerome Sherman
Journal:  J Optom       Date:  2016-12-28

8.  Linezolid-induced optic neuropathy.

Authors:  Divya Karuppannasamy; Andavar Raghuram; Devisundaram Sundar
Journal:  Indian J Ophthalmol       Date:  2014-04       Impact factor: 1.848
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.